Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults

NCT ID: NCT02474901

Last Updated: 2017-11-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 101 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-07-31
• Study Completion Date: 2016-12-31

Brief Summary

The goal of this study is to determine if there is a difference in shedding (primary objective) and in immunogenicity and safety (secondary objectives) between HIV-positive and HIV-negative children and young adults who are receiving the quadrivalent live-attenuated influenza vaccine (QLAIV).

Detailed Description

QLAIV is an intranasal vaccine that works by using 4 different attenuated strains of influenza virus that will replicate in the nose and stimulate an immune response in recipients that should protect them if they are infected with one of those strains of influenza in the future. A couple of studies have shown an increase in duration that the viruses remain in the nose in immunocompromised people. Those studies were done using the trivalent vaccine, so the investigators would like to evaluate the quadrivalent vaccine, and there is still a need for additional data to help understand the duration of shedding. If shedding is prolonged in HIV-infected children and young adults, it would be important to know for contacts of those individuals who are very immunocompromised. Shedding will be measured by looking for influenza RNA in nasopharyngeal swabs taken at baseline, 2-5 days, 7-10 days and 14-21 days after the intranasal immunization.

The live-attenuated influenza vaccines have been shown to have increased effectiveness in children and they stimulate the immune system in a different way than the inactivated influenza vaccines (TIV or QIV). In this study, the investigators will have the opportunity to compare the immunogenicity of QLAIV, measured at baseline and 14-21 days post-vaccination, in HIV-infected and uninfected children, adolescents and young adults. Although prior studies of LAIV in HIV-infected and other immunocompromised children and adults have not shown any increase in serious adverse events, safety will be actively monitored for the first 30-45 days through a study-specific questionnaire administered at each clinic or phone visit and by asking the subjects to keep a diary of side effects. Safety will be monitored passively throughout the course of the study.

Conditions

Human Immunodeficiency Virus (HIV)

Keywords

Shedding; Immunogenicity; Safety; HIV infected; Children; Young adults

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: NONE

Study Groups

QLAIV, HIV-infected

QLAIV administered to HIV-infected individuals 2 to 25 yoa

Group Type: ACTIVE_COMPARATOR

Quadrivalent Live Attenuated Influenza Vaccine

Intervention Type: BIOLOGICAL

QLAIV, HIV-uninfected

QLAIV administered to HIV-uninfected individuals 2 to 25 yoa

Group Type: ACTIVE_COMPARATOR

Quadrivalent Live Attenuated Influenza Vaccine

Intervention Type: BIOLOGICAL

Interventions

Quadrivalent Live Attenuated Influenza Vaccine

Intervention Type: BIOLOGICAL

Other Intervention Names

FluMist Quadrivalent; QLAIV

Eligibility Criteria

Inclusion Criteria

• Age 2-25
• Only supposed to get one dose of vaccine for upcoming influenza season
• No viral respiratory symptoms at time of immunization
• HIV-infected group: must have:

• HIV-infection documented by 2 tests such as positive serology, positive HIV DNA or positive HIV RNA;
• must thave a CD4>25% or 500, or
• must have CD4>15% or 200 and be on HAART
• Healthy controls: no major medical problems affecting the immune system
• Recruited among:

• HIV-unifected clients of the Children's Immunodeficiency Program(CHIP),
• Children's Hospital Colorado Child Health Clinic and Adolescent Clinics.

Exclusion Criteria

• History of:

• reactive airway disease,
• recurrent wheezing, or
• asthma
• Active wheezing at time of immunization
• On any antiviral agents active against influenza (amantadien/rimantadine, zanamavir, oseltamivir) at time of immunization or planned over 21 days of shedding collection
• Receipt of IVIG within 3 months prior to enrollment
• Plan to receive IVIG during the 4 weeks after immunization
• Moderate to severely immunocompromised individual living in the home
• Pregnant
• Breastfeeding
• Plan to start immunosupressive medications or stop HAART over the 4 weeks following immmunization
• Temperature > 100F or 37.8C
• Rhinorrhea or cough not related to allergies at the time of immunization
• History of fungal sinusitis
• History of Guillain-Barre Syndrome
• Current on antibiotics
• Currently taking aspirin
• On an investigational drug at the time of immunization or planned over the 28 days of shedding collection
• On any experimental medication at time of immunization or planned over 21 days of shedding collection

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 25 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

MedImmune LLC

INDUSTRY

Sponsor Role: collaborator

University of Colorado, Denver

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Adriana Weinberg, MD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Myron Levin, MD

Role: STUDY_CHAIR

University of Colorado, Denver

Donna Curtis, MD,MPH

Role: STUDY_DIRECTOR

University of Colorado, Denver

Locations

University of Colorado Denver

Denver, Colorado, United States

Countries

United States

Other Identifiers

13-1752

Identifier Type: -

Identifier Source: org_study_id